Catalio Capital Management
Latest statistics and disclosures from Catalio Capital Management's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0001958125
Tip: Access up to 7 years of quarterly data
Positions held by Catalio Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Catalio Capital Management
Catalio Capital Management holds 38 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 8.1 | $44M | 57k | 763.00 |
|
|
| Abbvie (ABBV) | 6.6 | $36M | 155k | 231.54 |
|
|
| Bridgebio Pharma (BBIO) | 6.0 | $32M | 623k | 51.94 |
|
|
| Intuitive Surgical Com New (ISRG) | 5.9 | $32M | 71k | 447.23 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 5.3 | $29M | 145k | 198.81 |
|
|
| Soleno Therapeutics (SLNO) | 5.2 | $28M | 418k | 67.60 |
|
|
| Dianthus Therapeutics (DNTH) | 4.9 | $26M | 668k | 39.35 |
|
|
| Boston Scientific Corporation (BSX) | 4.7 | $26M | 263k | 97.63 |
|
|
| Syndax Pharmaceuticals (SNDX) | 4.6 | $25M | 1.6M | 15.38 |
|
|
| Cytokinetics Com New (CYTK) | 4.6 | $25M | 452k | 54.96 |
|
|
| Natera (NTRA) | 4.4 | $24M | 148k | 160.97 |
|
|
| Regeneron Pharmaceuticals (REGN) | 3.7 | $20M | 35k | 562.27 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.4 | $18M | 652k | 28.00 |
|
|
| Uniqure Nv SHS (QURE) | 3.1 | $17M | 283k | 58.37 |
|
|
| Disc Medicine (IRON) | 2.6 | $14M | 217k | 66.08 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 2.5 | $14M | 162k | 84.90 |
|
|
| Supernus Pharmaceuticals (SUPN) | 2.5 | $14M | 287k | 47.79 |
|
|
| EXACT Sciences Corporation (EXAS) | 2.5 | $14M | 249k | 54.71 |
|
|
| Phathom Pharmaceuticals (PHAT) | 2.5 | $13M | 1.1M | 11.77 |
|
|
| Adaptive Biotechnologies Cor (ADPT) | 2.4 | $13M | 885k | 14.96 |
|
|
| Avidity Biosciences Ord (RNA) | 2.1 | $12M | 263k | 43.57 |
|
|
| Adma Biologics (ADMA) | 1.9 | $10M | 685k | 14.66 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 1.6 | $8.8M | 291k | 30.08 |
|
|
| Fractyl Health (GUTS) | 1.5 | $8.3M | 5.2M | 1.59 |
|
|
| Grail (GRAL) | 1.5 | $8.2M | 138k | 59.13 |
|
|
| Protara Therapeutics Com Stk (TARA) | 1.2 | $6.5M | 1.5M | 4.35 |
|
|
| Septerna (SEPN) | 1.0 | $5.5M | 294k | 18.81 |
|
|
| Cidara Therapeutics Com New (CDTX) | 0.9 | $5.1M | 53k | 95.76 |
|
|
| Kyverna Therapeutics (KYTX) | 0.7 | $3.5M | 587k | 6.00 |
|
|
| Eledon Pharmaceuticals (ELDN) | 0.5 | $2.7M | 1.1M | 2.59 |
|
|
| Outset Med Com New (OM) | 0.3 | $1.7M | 118k | 14.12 |
|
|
| Metagenomi (MGX) | 0.2 | $1.3M | 529k | 2.37 |
|
|
| Atai Life Sciences Nv SHS (ATAI) | 0.2 | $1.0M | 197k | 5.29 |
|
|
| Hyperfine Com Cl A (HYPR) | 0.2 | $993k | 685k | 1.45 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.2 | $955k | 133k | 7.17 |
|
|
| Karyopharm Therapeutics Com New (KPTI) | 0.2 | $935k | 143k | 6.54 |
|
|
| Palvella Therapeutics Inc Ne (PVLA) | 0.1 | $753k | 12k | 62.69 |
|
|
| Sensei Biotherapeutics Com New (SNSE) | 0.0 | $139k | 15k | 9.45 |
|
Past Filings by Catalio Capital Management
SEC 13F filings are viewable for Catalio Capital Management going back to 2025
- Catalio Capital Management 2025 Q3 filed Nov. 14, 2025